( AGIX) dropped nearly 60% after the company's heart-disease drug failed to reach its primary goal in a Phase III trial. The stock was tumbling $4.63 at $3.20.
( SEPR) was also trading lower after Friedman Billings downgraded the stock to underperform from market perform. The firm also cut its stock price target for Sepracor to $43 from $58, citing weaker-than-expected sales of the company's sleep drug Lunesta. Sepracor was off $1.24, or 2.6%, to $46.62.
was rising 2.8% to $69.97.
tacked on 2.4% to $54.39.
( WYE) was higher by 2.1% at $49.27.
( HEPH) was down 6.2% to $3.05.
was falling 3.7% to $1.32.
( CVTX) was lower by 1.8% at $9.13.